The activation of the cGAS-STING pathway was also evident during liver inflammation, such as that observed in non-alcoholic fatty acid liver disease (NAFLD), hepatocellular carcinoma, cirrhosis, and viral hepatitis37. This evidence concerns the gene STING1 and metabolic dysfunction-associated steatotic liver disease.